ClinicalTrials.gg
CompletedNCT00124722Updated Jun 1, 2015

A Study to Compare Different Intubating Doses of Zemuron in Pediatric and Adolescent Subjects Under General Anesthesia

A Phase 3 interventional study of Rocuronium bromide (Zemuron) and Rocuronium bromide (Zemuron) in Anesthesia, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged Up to 17 Years. Per ClinicalTrials.gov, last updated 2015-06-01.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
207
Allocation
Randomized
Ages
Up to 17 Years
Sex
All
01

Study summary

The primary purpose of this study is to evaluate the time course of muscle relaxation after administration of three different single intravenous bolus doses of rocuronium bromide for intubation (insertion of a tube through the nose or mouth into the trachea to provide artificial ventilation) in term neonates (birth to \<28 days old), infants (28 days to \<=3 months) and toddlers (>3 months to \<=2 years), children (2 years to less than or equal to 11 years of age), and adolescents (>11 years to less than or equal to 17 years of age).

Subjects in each of the age groups will be randomized to one of 3 Zemuron® doses: 0.45 mg/kg, 0.6 mg/kg, or 1.0 mg/kg.

02

Conditions studied

  • Anesthesia
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects from birth up to 17 years of age who will be scheduled for surgery under general anesthesia.

Exclusion criteria

Exclusion Criteria:

  • Subjects whose parent(s) or legal guardian(s) are not willing to give written consent and where applicable, subjects who have not given appropriate assent to participate in the trial will not be allowed to enter.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
207 participants (actual)

Study arms

  • Experimental
    0.45 mg/kg Zemuron

    0.45 mg/kg Zemuron

    Drug: Rocuronium bromide (Zemuron)

  • Active comparator
    0.6 mg/kg Zemuron

    0.6 mg/kg Zemuron

    Drug: Rocuronium bromide (Zemuron)

  • Experimental
    1.0 mg/kg Zemuron

    1.0 mg/kg Zemuron

    Drug: Rocuronium bromide (Zemuron)

Interventions

  • A single IV Zemuron bolus dose of 0.45 mg/kg prior to intubation.

    Also known as: ORG 9426, SCH 900085, Zemuron

  • A single IV Zemuron bolus dose of 0.6 mg/kg prior to intubation.

    Also known as: ORG 9426, SCH 900085, Zemuron

  • A single IV Zemuron bolus dose of 1.0 mg/kg prior to intubation.

    Also known as: ORG 9426, SCH 900085, Zemuron

06

What researchers measure

Primary outcomes

  1. Time to reappearance of T3 (time from end-administration of Zemuron to reappearance of the third twitch of a TOF stimulation)

    Time frame: during surgery

Secondary outcomes

  1. Onset time, maximum block, time to reappearance of T1, Recovery to TOF 0.7, 0.8 and 0.9 and intubation score

    Time frame: during and after surgery

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Tirotta CF, Brandom B, Siddiqui MS, Ehlers M, Betzel J, Chen J-Y, De Bie J, Blobner M. Time Course of Rocuronium-Induced Neuromuscular Blockade in Pediatric Patients: A Phase III, Randomized, Dose-Response Study. J Anesthe Clin Res. 2012;3:189.
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2004, a primary completion of Jul 2007 and a completion of Jul 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2005
First posted
Jul 28, 2005
Start
Dec 2004
Primary completionActual
Jul 2007
CompletionActual
Jul 2007
Last update
Jun 1, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00124722
Responsible party
Sponsor
First posted
Jul 28, 2005
Start date
Dec 2004
Primary completion
Jul 2007
Completion
Jul 2007
Last update
Jun 1, 2015

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rocuronium

Start the discussion